ACE Inhibitor Intolerance
Sodium-glucose cotransporter type 2 inhibitors: A new era in the pharmacological treatment of heart failure with reduced ejection fraction?
Charm | PDF | Heart Failure | Medical Treatments
Ontarget
![PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/44636c2520238a6bf7f2c73b6a8ede4a08468856/3-Figure2-1.png "PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Semantic Scholar")
PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Semantic Scholar
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial - The Lancet
ARBs in HFrEF (ELITE I & II, CHARM-Alternative, CHARM-Added & Val-HeFT) — NERDCAT
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - The Lancet
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction | Circulation
CHARM Program: 3 Component trials comparing candesartan with placebo. - ppt download
JCDD | Free Full-Text | Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?
Results of the CHARM trial program. 52–55 Notes: *p for heterogeneity... | Download Scientific Diagram
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - ScienceDirect
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial - ScienceDirect
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction | NEJM
Design of the CHARM programme | Download Scientific Diagram
ACE Inhibitor Intolerance
Cumulative number of hospital admissions: CHARM-Alternative (top left),... | Download Scientific Diagram
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction | Circulation
Figure 2 from Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar
PPT - CHARM Program: 3 Component trials comparing candesartan with placebo PowerPoint Presentation - ID:4521239
![PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/569ebf85700d1ed65585fd33c90b0480ff26f05b/2-Figure1-1.png "PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar")
PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - The Lancet
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin. - ppt video online download
PPT - Candesartan in Heart Failure PowerPoint Presentation, free download - ID:5679543
